Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,621Revenue $M13.9Net Margin (%)-235.2Z-Score7.2
Enterprise Value $M2,530EPS $-1.2Operating Margin %-143.2F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-241.6Higher ROA y-yN
Price/Book7.310-y EBITDA Growth Rate %0Quick Ratio4.2Cash flow > EarningsN
Price/Sales54.35-y EBITDA Growth Rate %0Current Ratio4.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-22.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M100ROI % (ttm)-110.7Gross Margin Increase y-yN

Gurus Latest Trades with XON

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
XONDavid Einhorn 2014-09-30 Reduce-0.06%$17.86 - $26.59
($21.29)
$ 26.0722%Reduce -47.39%197,278
XONJean-Marie Eveillard 2014-06-30 Buy 0.04%$15.3 - $25.93
($21.15)
$ 26.0723%New holding, 661564 sh.661,564
XONDavid Einhorn 2014-06-30 Reduce-0.39%$15.3 - $25.93
($21.15)
$ 26.0723%Reduce -72.81%375,000
XONDaniel Loeb 2014-03-31 Add0.18%$22.5 - $36.82
($28.82)
$ 26.07-10%Add 18.15%3,000,000
XONDavid Einhorn 2014-03-31 Reduce-0.26%$22.5 - $36.82
($28.82)
$ 26.07-10%Reduce -37.58%1,379,014
XONDaniel Loeb 2013-12-31 Add0.15%$17.65 - $25.5
($21.05)
$ 26.0724%Add 18.07%2,539,200
XONDaniel Loeb 2013-09-30 Buy 1.2%$21.36 - $29.7
($24.16)
$ 26.078%New holding, 2150592 sh.2,150,592
XONDavid Einhorn 2013-09-30 Buy 0.86%$21.36 - $29.7
($24.16)
$ 26.078%New holding, 2176868 sh.2,176,868
XONT Boone Pickens 2013-09-30 Buy 0.47%$21.36 - $29.7
($24.16)
$ 26.078%New holding, 12000 sh.12,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

XON is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
XON Jean-Marie Eveillard 2014-09-30790,3640.790.04+19.47%
XON Daniel Loeb 2014-09-302,900,0002.890.62
XON David Einhorn 2014-09-30197,2780.20.05-47.39%
XON T Boone Pickens 2013-09-3012,0000.010.47New Buy
Premium Most recent portfolio changes are included for Premium Members only!


XON: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
KIRK RANDAL JCEO, 10% Owner 2014-05-13Buy65,173$15.1971.63view
Reed Thomas D.Chief Science Officer 2014-05-13Buy640$15.667.12view
Lehr Donald P.Chief Legal Officer 2014-05-13Buy1,850$15.9963.04view
Huang KellySVP-Consumer Sector 2014-05-09Buy3,200$15.7865.21view
Kasser Thomas R.SVP--Food Sector 2014-05-09Buy10,000$13.3994.7view
Krishnan Krish SCOO 2014-05-09Buy20,900$14.2183.46view
Krishnan SumaSVP--Product Development 2014-05-09Buy20,900$14.2183.46view
KIRK RANDAL JCEO, 10% Owner 2014-05-09Buy67,333$15.1671.97view
KIRK RANDAL JCEO, 10% Owner 2014-03-27Buy243,001$25.721.36view
Frost Gregory IanSVP--Health Sector 2014-03-04Buy100,000$25.950.46view

Press Releases about XON :

    Quarterly/Annual Reports about XON:

    News about XON:

    Articles On GuruFocus.com
    5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
    Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
    Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
    David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
    Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

    More From Our Partners
    Tracking David Einhorn's Portfolio - Q3 2014 Update Nov 20 2014 - SEEKINGALPHA

    More From Other Websites
    INTREXON CORP Financials Nov 21 2014
    Can the Rally in Intrexon (XON) Shares Continue? Nov 19 2014
    Fibrocell Science Announces IND Allowed to Proceed to Develop New Treatment for Wounded Warrior... Nov 18 2014
    Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
    INTREXON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 13 2014
    Intrexon Announces Third Quarter 2014 Financial Results Nov 13 2014
    Q3 2014 Intrexon Corp Earnings Release - After Market Close Nov 13 2014
    ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014
    ROI Land Investments Ltd. Closes $6,000,000 Equity Investment Nov 12 2014
    Will Higher Expenses Hurt Intrexon (XON) Earnings in Q3? Nov 12 2014
    Intrexon (XON) Looks Good: Stock Moves 11% Higher Nov 12 2014
    Herb's seeing green: XON Nov 11 2014
    Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301,... Nov 10 2014
    Fibrocell Science Reports Third Quarter and Nine Month 2014 Financial and Operating Results Nov 07 2014
    Study Demonstrates Automated Laser-based Cell Manipulation with Intrexon's Proprietary LEAP® System Nov 06 2014
    Study Demonstrates Automated Laser-based Cell Manipulation with Intrexon's Proprietary LEAP® System Nov 06 2014
    Intrexon to Announce Third Quarter 2014 Results and Host Conference Call on November 13th Nov 06 2014
    Intrexon to Announce Third Quarter 2014 Results and Host Conference Call on November 13th Nov 06 2014
    Fibrocell Science to Report Third Quarter 2014 Financial and Operating Results, and Host Conference... Oct 30 2014
    SEC Warned Before About Early Release Weak Spot Oct 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK